Cure8 news brief
A new patient-derived “Colon Chip” reproduces key features of Crohn’s disease and ulcerative colitis in the lab and points to fibroblasts as active drivers of inflammation and early cancer-associated changes — insights that could guide future research and drug testing.
Researchers, clinicians, drug developers, and patients interested in IBD disease mechanisms and translational models.
A team created a patient-derived “Colon Chip” that combines matched epithelial cells, stromal fibroblasts, circulating immune cells and mechanical stretching to model IBD in vitro.
Using cells from people with Crohn’s disease and ulcerative colitis, the chips reproduced multiple disease features — reduced mucus, thinner epithelial layers, heightened inflammatory and fibrotic responses — and suggested fibroblasts can drive inflammation and weaken the barrier.
The researchers used the chip to model early stages of colorectal cancer by exposing tissues to a carcinogen; chips built from IBD donors showed stronger cancer-associated molecular changes, and fibroblasts from IBD patients could induce early cancer markers in otherwise healthy epithelium.
This is an in vitro (lab) study using a microphysiological chip and patient cells reported in Nature Biomedical Engineering; it provides mechanistic insight but not clinical trial results. Interpret findings as preclinical research rather than proven patient therapies.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
The finding links a specific mucus-associated protein (HMGB1) to barrier defects in Crohn’s disease, which could help explain how bacteria reach and inflame tissue in active lesions and point to future biomarker or...
This paper links specific features of the gut bacterial flagellome to TLR5-driven immune activation and reports a disease-associated shift in flagellin profiles in Crohn’s disease and ulcerative colitis, suggesting...
Researchers are exploring circRNAs as new molecular players in IBD inflammation; that could lead to future biomarker tests or novel treatments targeting immune pathways relevant to Crohn’s disease and ulcerative colitis.
